No data to show
OTCM
TIHE
Market cap0kUSD
Mar 03, Last price
0.00USD
Name
Taihe Group Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-44k
L+50.47%
CFO
-42k
L+43.33%
Profile
Taihe Group, Inc. does not have significant operations. Previously, it was operated as commercial laboratory and provided predictive chemosensitivity and immunotherapy predictive tests on biopsy tissues and other oncological laboratory testing services and products. The company was formerly known as NuOncology Labs, Inc. and changed its name to Taihe Group, Inc. in April 2022. Taihe Group, Inc. was incorporated in 1994 and is based in Scottsdale, Arizona.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY |
|---|---|---|---|
| 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | |||
Revenues | |||
Cost of revenue | 44 | ||
Unusual Expense (Income) | |||
NOPBT | (44) | ||
NOPBT Margin | |||
Operating Taxes | |||
Tax Rate | |||
NOPAT | (44) | ||
Net income | (44) 50.47% | ||
Dividends | |||
Dividend yield | |||
Proceeds from repurchase of equity | |||
BB yield | |||
| Debt | |||
Debt current | 42 | ||
Long-term debt | |||
Deferred revenue | |||
Other long-term liabilities | 2 | ||
Net debt | 42 | ||
| Cash flow | |||
Cash from operating activities | (42) | ||
CAPEX | |||
Cash from investing activities | |||
Cash from financing activities | 42 | ||
FCF | (42) | ||
| Balance | |||
Cash | |||
Long term investments | |||
Excess cash | |||
Stockholders' equity | (10,872) | ||
Invested Capital | 10,870 | ||
ROIC | |||
ROCE | 2,107.72% | ||
| EV | |||
Common stock shares outstanding | 63 | ||
Price | 1.56 | ||
Market cap | 98 | ||
EV | 150 | ||
EBITDA | (44) | ||
EV/EBITDA | |||
Interest | |||
Interest/NOPBT | |||